Eli Lilly Other — Revenue decreased by 43.2% to $191.40M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 0.4%, from $190.70M to $191.40M. Over 4 years (FY 2021 to FY 2025), Other — Revenue shows a downward trend with a -30.9% CAGR.
An increase suggests successful lifecycle management or unexpected demand for legacy products, while a decrease may indicate portfolio pruning or the natural decline of older, off-patent medications.
This metric represents the total net sales generated from pharmaceutical products that do not fall into the company's pr...
Peers typically report this as 'Other' or 'Legacy' product revenue, often representing a declining percentage of total sales as companies shift focus toward high-growth therapeutic areas.
lly_segment_other_product_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $712.90M | $637.70M | $1.54B | $1.92B | $494.70M | $746.00M | $356.00M | $275.30M | $314.60M | $276.10M | $256.20M | $241.90M | $207.60M | $262.80M | $190.70M | $212.90M | $201.50M | $337.20M | $191.40M |
| QoQ Change | — | -10.5% | +140.9% | +25.2% | -74.3% | +50.8% | -52.3% | -22.7% | +14.3% | -12.2% | -7.2% | -5.6% | -14.2% | +26.6% | -27.4% | +11.6% | -5.4% | +67.3% | -43.2% |
| YoY Change | — | — | — | — | -30.6% | +17.0% | -76.8% | -85.7% | -36.4% | -63.0% | -28.0% | -12.1% | -34.0% | -4.8% | -25.6% | -12.0% | -2.9% | +28.3% | +0.4% |
We use cookies for analytics. See our Privacy and Cookie Policy.